[Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
OBJECTIVE
To evaluate the clinical efficacy of etofibrate in primary hyperlipidemia in patients from clinical centers representative of all main Brazilian cities.


METHODS
One thousand, nine hundred and fourty three hyperlipidemic patients were submitted to diet and drug treatment with etofibrate (500 mg/day) for eight weeks. The data b WAS analyzed as to changes in the lipoprotein profile, as well as the side effects.


RESULTS
There was an important reduction in total cholesterol (19.88%), triglycerides (29.59%), LDL-c (14.89%) and VLDL-c (14.54%) concentration. There was a significant increase in HDL-c (18.14%). Adverse effects were observed in 8.5% of the patients, without major clinical relevance, however, in 1.44% the treatment had to be interrupted.


CONCLUSIONS
Administration of etofibrate promoted positive changes in all parameters of the lipid and lipoprotein profile, thus reducing the risk of atherosclerotic disease, without significant side effects in the great majority of sample studied.
dos Santos
J E
JE
Faculdade de Medicina de Ribeirão Preto-USP.
Loures-Vale
A A
AA
Novazzi
J P
JP
Rabelo
L M
LM
Martinez
T L
TL
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002784:Cholesterol / Q000097:blood; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D014280:Triglycerides; C009746:etofibrate; D002995:Clofibric Acid; D002784:Cholesterol
Avaliação da eficácia e segurança do etofibrato em pacientes dislipidêmicos. Estudo multicêntrico.